Tagged with clinical

Mexico According to a recent World Health Organization study, countries must allocate at least six percent of their GDP to research and development to be considered to have a healthy investment in this area. As Mexico currently only invests 1.8 percent of its GDP into R&D, there is clearly still a…

Ukraine Tetyana Dumenko, director of the State Expert Center (SEC) of the Ministry of Health of Ukraine, the regulatory agency responsible for product registration, pre-clinical studies and clinical trials approval and pharmacovigilance, provides insights into some of her initial achievements since taking the position and her main strategic priorities to further…

Mexico Marco Cid, Director General of Investigacion Biomedica, shares how he successfully launched an innovative clinical research center (CRC) despite a challenging regulatory environment. He speaks about the inspiration behind his business model, the necessity of building a strong rapport with authoritative entities in the market, as well as fostering a…

Mexico The CEO of Accelerium Clinical Research, Ciro Garcia speaks about the trends currently impacting Mexico’s clinical research space, while detailing the company’s ambition to pivot from just one full-service research center to the nation’s leading network of clinical research facilities. Could you please introduce yourself to our international audience as…

Mexico Positioning itself as a flexible local CRO with an in-depth knowledge of the Mexican market, iLS Clinical Research CEO, Alejandro Arias, shares his insights on how to be the ideal partner for international expansion. He speaks about the company’s milestones and background, navigating through the challenges of the Mexican CRO…

Mexico With an impressive achievement of growing the novel “flexible solutions” business unit by an astounding 50 percent in his first year of spearheading the region, Ricardo Uribe, Covance Mexico’s Director of Country Operations, shares his insights into the attractiveness of the region for clinical research. He speaks about the impressive…

Switzerland Despite increasing consolidation in the clinical trial industry, there’s enough market share to go around says SOCAR Research CEO Bridget-Anne Kirwan. For SOCAR Research, it’s the company’s strong academic roots in addition to personalized, tailored and innovative services that have helped to make the difference. To begin, could you please…

Taiwan With more than 100 peer-reviewed articles published and more than ten thousand citations, Guochuan Emil Tsai, founder and CEO of SyneuRx and Professor at the department of Psychiatry and Behavioral sciences at the University of California, Los Angeles (UCLA), is an internationally reputed scientist in neurosciences and brain disorders, whose…

Mexico Arturo Rodríguez Jacob, CEO at Infinite Clinical Research (ICR) and president of the national association of CROs (ACROM), explains what make Mexico the regional clinical research hub and showcases how ICR is developing clinical studies for allopathic, biotech, medtech, and herbal medicine companies. Only 15 years ago, the Mexican clinical…

Greece Ioanna Koukli, the owner and founder of Pharmassist Ltd, began the company with a vision of assisting healthcare companies manoeuver through the European regulatory milieu. Today, with Pharmassist established as a full service CRO, Koukli discusses the company’s evolution, the potential of clinical trials in Greece, as well as fostering…

Greece In a landscape starved for innovative medicine, clinical trials stand as a beacon of hope for critical care patients in need of the latest high-value treatments. Pioneering the development of a thriving CRO environment is Andreas Moschos, founder of NextCRO, who fully embodies the forward-thinking values invoked by the company’s…

Mexico Enrique Carballido, general manager Mexico and Latin South America at Bio-Rad, showcases Bio-Rad’s offering in both diagnostics and life sciences and the crucial role of the entire industry in helping public health institutions more effectively allocate their resources based on the number of patients covered and the economical savings obtained.…